Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
November 02, 2023
Geopolitical risks are rapidly converging, making the world more crisis-prone and precarious. Faced with a near economic collapse in some low and lower middle-income countries, the escalating devastation of climate-related disasters aggravating existing vulnerabilities, and a sharp rise in conflicts...
Blog Post
September 27, 2023
The rapid evolution of the development landscape, amid ongoing crises such as the war in Ukraine and climate change, presents profound challenges for all development actors. The various challenges intersect in unprecedented ways, amplifying the complexities faced by development cooperation providers...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 13, 2023
For 20 years, the Commitment to Development Index has assessed countries' policies and the level of effort they go to in order to contribute to international development. Because development depends on much more than foreign aid, the Index looks at countries’ performance across eight different polic...
Blog Post
September 07, 2023
We have reviewed each of the UK’s seven main finance tools—from export finance to capital increases at its private finance arm, British International Investment. Overall, we find that the UK has substantially increased the level of finance it mobilises, from around £3bn in 2018, to £5bn in 2021, and...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...